Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?

Eitemau Tebyg

• Therapeutic drug monitoring and tyrosine kinase inhibitors
  gan: Herviou, Pauline, et al.
  Cyhoeddwyd: (2016)
• Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
  gan: Brindel, Aurélien, et al.
  Cyhoeddwyd: (2020)
• Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
  gan: Riediger, Anja Lisa, et al.
  Cyhoeddwyd: (2016)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  gan: Chen, Zhi-Yong, et al.
  Cyhoeddwyd: (2012)
• Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
  gan: Nicoś, Marcin, et al.
  Cyhoeddwyd: (2019)